138th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2170401296151939 Karnataka164924842322998 Delhi1441271293624098 Uttar Pradesh118038698332028 West Bengal89666630601954 Telangana7751354330615 Bihar7578648673419 Gujarat68855517922604 Assam5549737225132 Rajasthan5065636310776 Odisha4419328698307 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3312020862107 Jammu and Kashmir2439020862459 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Tripura6014408437 Puducherry5123291475 Manipur3635192711 Himachal Pradesh3242201513 Nagaland26888937 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
Science 11 Jul 2020 DCGI okays trial of ...

DCGI okays trial of skin care drug for COVID-19

PTI
Published Jul 11, 2020, 6:45 pm IST
Updated Jul 11, 2020, 8:34 pm IST
Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing the drug.
Representational image.
 Representational image.

New Delhi: Based on clinical trials data, India's drug regulator has approved itolizumab, used to treat skin condition psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, the Union health ministry said on Saturday.

Considering the unmet medical needs in COVID-19, Drugs Controller General of India (DCGI) Dr V G Somani had on Friday approved itolizumab injection for use in the treatment of coronavirus patients.

 

Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing Itolizumab, a monoclonal antibody drug, for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under the brand name Alzumab, the health ministry said.

"This indigenous drug has now been repurposed for COVID-19," it said in a statement.

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office.

"After detailed deliberation and taking into account the recommendations of the committee, the DCGI has decided to grant permission to market the drug under restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19," it said.

 

The use of the medicine is subject to some conditions including requirement of informed consent of patients, a risk management plan and usage only in hospital setup.

The average cost of treatment with this indigenous drug Itolizumab is lesser than other medicines which are part of investigational therapies indicated in the health ministry's Clinical Management Protocols for COVID-19.

Click on Deccan Chronicle Technology and Science for the latest news and reviews. Follow us on Facebook, Twitter

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT